Si deseas distinguir tus productos, servicios o ambos de los de otra empresa, es posible que necesites una marca o nombre comercial. Descubre qué son, en qué consiste su procedimiento de registro y qué implica.
Información sobre los plazos de presentación de solicitudes de transformación de marcas de la Unión Europea en marca nacional española. Más información
Si tienes un nuevo dispositivo, producto o procedimiento que resuelva un problema técnico o tenga una ventaja práctica, existen distintas formas de protegerlo en España y en otros países. Descubre cómo hacerlo.
¿Tu innovación reside en la estética, la ornamentación o la apariencia de tu producto? Protégela mediante un diseño industrial. Descubre qué derechos confiere el registro y cómo realizar la tramitación.
Las patentes publicadas en todo el mundo son una valiosa fuente de información científica, técnica y comercial.
El Bono 3 del Fondo para pymes 2025, que cubre la elaboración de Informes Tecnológicos de Patentes (ITP) y Búsquedas Retrospectivas se cerrará el miércoles 18/06/2025 al final de la jornada laboral. Puede consultar más información aquí.
Si eres emprendedor/a o una empresa y quieres potenciar y mejorar la rentabilidad de tu negocio protegiendo de forma adecuada los activos intangibles de tu organización, en este espacio encontrarás lo necesario.
56
resultados
Última actualización
21/06/2025 [08:38:00]
Resumen de: WO2024052650A1
The invention relates to neurodegenerative disorders, and the diagnosis and/or prognosis of neurodegenerative disorders in a test subject using a lateral flow test, or the like. The invention also relates to detecting diagnostic and prognostic biomarkers in a range of various patient sample types for diagnosing and/or prognosing neurodegenerative disorders, such as Alzheimer's disease. The invention further provides biomarker detection methods, and apparatus and apparatuses for diagnosing and prognosing neurodegenerative disorders, and methods of treating patients diagnosed or prognosed with a neurodegenerative disorder. The invention also extends to detection of biomarkers and/or screening in pre-symptomatic subjects, for early diagnosis, to enable disease prevention or intervention.
Resumen de: WO2025123398A1
An Alzheimer's disease biomarker based on a brain metabolite and a use thereof. The biomarker comprises any one or a combination of at least two of palmitic acid, DHA, gallic acid, 11Z,14Z,17Z-eicosatrienoic acid, glycodeoxycholic acid, palmitoleic acid, linoleic acid, erucic acid, petroselinic acid, and arachidonic acid. The level of a metabolite is detected to assist in early diagnosis of the Alzheimer's disease, thus facilitating rapid detection; in addition, the present invention has the characteristics of timeliness, convenience, high specificity and high sensitivity.
Resumen de: WO2025123283A1
The use of a reagent, which detects changes in the concentration or number of immune cells and immune factors in the peripheral circulatory system and cerebrospinal fluid, in the preparation of a diagnostic tool or a therapeutic tool for diagnosing or monitoring Alzheimer's disease. A method for diagnosing or monitoring Alzheimer's disease, in which a reagent for detecting immune cells and immune factors in the peripheral circulatory system and cerebrospinal fluid is used to detect changes in the concentration or number of the immune cells and immune factors in the peripheral circulatory system and cerebrospinal fluid. A method for treating Alzheimer's disease, in which immune cells and immune factors in the peripheral circulatory system and cerebrospinal fluid are taken as targets for administration so as to reduce or decrease the concentration or number of the immune cells and immune factors.
Resumen de: WO2025125705A1
An in vitro procedure for diagnosing or determining the risk of a person developing Alzheimer's disease (AD), said procedure detecting and quantifying the expression products of the LMNA gene (SEQ. ID: No. 3): lamin A protein (SEQ. ID: No. 1) and its precursor prelamin A (SEQ. ID: No. 2), in a sample of peripheral nerve or smooth muscle.
Resumen de: EP4570823A1
The present invention relates to an improved antibody specifically binding to amyloid-β oligomers (AβOs). Specifically, the present invention relates to an improved form of the antibody W20. Compared with the antibody W20, the improved form of the antibody W20 has a significantly improved affinity to AβOs, and can more significantly inhibit the aggregation of Aβ and the AβOs-induced toxicity of nerve cells, more effectively improve the cognition and memory functions of an Alzheimer's disease model mouse, and reduce pathological changes in the brain of the mouse. The improved form of the antibody can specifically bind to oligomers of an amyloid-β, α-synuclein, mHTT and SOD 1, can inhibit the aggregation and cytotoxicity of various amyloids, and has a better potential for treating various amyloid diseases, such as Parkinson's disease, Huntington's disease, and amyotrophic lateral sclerosis, than the antibody W20. The improved form of the antibody can specifically bind to a highly toxic amyloid protein oligomer Aβo*3F, and has a better AD diagnosis value. The amino acid sequence of the antibody W20 is as shown in SEQ ID NO: 1.
Resumen de: EP4571315A1
A use of a new highly toxic amyloid oligomer Apo*3F as a target for diagnosing Alzheimer's disease (AD) in the early stage and the middle-late stage and mild cognitive impairment (MCI) caused by AD. The Aβo*3F specifically binds to an antibody 3F and is present in cerebrospinal fluid (CSF), blood and/or brain tissue of AD patients and patients with MCI caused by AD, and the levels show highly significant differences in CSF, blood and/or brain tissue of AD patients, MCI patients and healthy elderly persons. In addition, the Apo*3F is an ultra-highly toxic oligomer, is the most important toxic component in an Aβ oligomer mixture, has a strong pathogenic effect, and plays a key role in the occurrence and development of AD.
Resumen de: AU2023357033A1
The present disclosure generally relates to the surprising discovery that subjects likely to respond to treatment with an 11β-HSD1 inhibitor can be selected for treatment based on a comparison between a baseline level of a tau protein in the subject, and a reference level of the tau protein.
Resumen de: US2025189517A1
A solution is described for preserving cells and/or extra cellular components in naturally expressed bodily fluids (e.g. saliva, sputum, urine) for further downstream analysis and/or for diagnosis of a medical condition. The solution may be hypertonic with respect to blood. Techniques are described for enriching cells from a sample of a naturally expressed bodily fluid, and/or for analysis, e.g. to diagnose medical conditions such as cancer, obesity, infections, autism, Alzheimer disease, hetotological disorders, cardiovascular disease or disorders, diabetes, vulnerable plack, LTBI, HIV infection, COPD, ACQS.
Resumen de: US2025191903A1
Provided are methods for determining the apolipoprotein E (ApoE) phenotype in a sample by mass spectrometry; wherein the ApoE allele(s) present in the sample is determined from the identity of the ions detected by mass spectrometry. In another aspect, provided herein are methods for diagnosis or prognosis of Alzheimer's disease or dementia.
Resumen de: US2025189536A1
The present application provides methods, compositions and kits for determining SHD catabody levels in a biological sample, and for treating or preventing a protein aggregation disease (PAD) in an individual. Also provided are catabodies specifically recognizing amyloid beta (Aβ) peptides and methods of use thereof.
Resumen de: US2025189543A1
A method for quantifying active orexin A in a specimen, comprising: a step of contacting the specimen with a monoclonal antibody that recognizes the C-terminal side of orexin A to separate orexin A species; a step of digesting the separated orexin A species with a protease to obtain a peptide consisting of an amino acid sequence of SEQ ID NO: 1; and a step of performing mass spectrometry on the peptide.
Resumen de: EP4567427A1
A method for distinguishing or differentially diagnosing Alzheimer's disease from other neurodegenerative diseases, comprising determining the level of TPK1 protein in a sample from a subject, wherein a decrease in the level of TPK1 protein compared to a reference value indicates that the subject has Alzheimer's disease. Methods, compositions, test strips, test cards and/or kits for distinguishing or differentially diagnosing Alzheimer's disease from other neurodegenerative diseases by detecting a biomarker, wherein the methods, compositions, test strips, test cards and/or kits can specifically diagnose Alzheimer's disease.
Resumen de: AU2023356443A1
Provided is a protein marker Nell-1, which is present in a person's blood sample in an amount that is correlated with neurodegenerative disorders such as Alzheimer's Disease (AD), Mild Cognitive Impairment (MCI), and Parkinson's Disease (PD). Corresponding diagnostic and treatment methods for these neurodegenerative disorders as well as kits for diagnosing or treating the neurodegenerative disorders are also provided.
Resumen de: US2022373562A1
The present disclosure relates generally to a sensor chip and methods for the detection of an analyte. In particular, the disclosure relates to a sensor chip for detecting an analyte in a subject suffering from a neurodegenerative disease. The sensor chip comprises a conductive layer on a membrane support layer, wherein a plurality of apertures extend through the conductive layer and the membrane support layer and are arranged such that illumination of the conductive layer and/or the membrane support layer produces a surface plasmon resonance.
Resumen de: WO2025113506A1
The present invention relates to the field of biomedicine. Provided are a marker that can be used for early diagnosis of Alzheimer's disease, and the use thereof. Specifically provided is a marker for early diagnosis of Alzheimer's disease. The marker is a Maf1 gene or the protein thereof. High expression of the Maf1 gene or the protein thereof in neuronal cells indicates that a subject is at high risk of developing Alzheimer's disease. The method provides a new diagnostic and therapeutic target for AD.
Resumen de: US2025179489A1
An optimized method based on a dual promoter vector of the reprogramming factors combined with knock-down of the neural silencing complex RESTi to convert adult fibroblasts into induced neurons (iNs). We have also designed and cloned vector constructs of which some include all these components which allows for a one-step method to efficiently reprogram dermal fibroblasts including those obtained from elderly individuals. The single vector system can be used to obtain iNs of high yield and purity from biopsies from aged individuals with a range of familial and sporadic neurodegenerative disorders including Parkinson's, Huntington's as well as Alzheimer's disease.
Resumen de: WO2024026413A2
Methods, systems and kits useful for the detection and diagnosis of neurodegenerative diseases including Alzheimer's Disease (AD)- and early-stage Parkinson's Disease-related pathology, and methods of preparing labeled immunocomplexes useful for detecting AD- and PD-related pathology are provided.
Resumen de: CN118388648A
The invention discloses an anti-human PD-L1 antibody based on a fully human antibody mouse or an antigen binding fragment thereof, a nucleic acid molecule for coding the antibody or the antigen binding fragment, and a preparation method and application of the antibody or the antigen binding fragment. The anti-human PD-L1 antibody or the antigen binding fragment thereof is a fully humanized sequence, has good specificity and affinity to PD-L1, and can effectively promote secretion of IL2 and IFN gamma of T cells. And the immunogenicity is lower. The invention further relates to a pharmaceutical composition containing the antibody or the antigen binding fragment thereof and application of the antibody or the antigen binding fragment thereof in preparation of drugs for preventing and/or treating PD-L1 related diseases.
Resumen de: CN118388648A
The invention discloses an anti-human PD-L1 antibody based on a fully human antibody mouse or an antigen binding fragment thereof, a nucleic acid molecule for coding the antibody or the antigen binding fragment, and a preparation method and application of the antibody or the antigen binding fragment. The anti-human PD-L1 antibody or the antigen binding fragment thereof is a fully humanized sequence, has good specificity and affinity to PD-L1, and can effectively promote secretion of IL2 and IFN gamma of T cells. And the immunogenicity is lower. The invention further relates to a pharmaceutical composition containing the antibody or the antigen binding fragment thereof and application of the antibody or the antigen binding fragment thereof in preparation of drugs for preventing and/or treating PD-L1 related diseases.
Resumen de: AU2023334129A1
The invention relates to identification of an intron-retaining Tau splicing isoform as a novel Alzheimer's disease biomarker. Provided herein are polypeptides to generate binding molecules, such as antibodies specific for the Tau11i isoform, oligonucleotides and antibodies for use in methods for detecting the Tau11i isoform in a sample and methods for use in diagnosis for Alzheimer's disease.
Resumen de: US2025060376A1
The present application relates to a digested DDIT4L product as a diagnostic marker for Alzheimer's disease, and use thereof in diagnosing Alzheimer's disease. In particular, the present application relates to use of a substance for detecting a digested intron retention (DIR) product encoding DNA-damage-inducible transcript 4 like (DDIT4L) in a sample of a subject in preparing a product for diagnosing Alzheimer's disease or a mild cognitive disorder and/or assessing (e.g., grading or staging) cognitive disorder progression, a related product thereof, and a method for screening a medicament using the DIR product.
Resumen de: AU2023347307A1
The disclosure relates to lemborexant, a dual orexin receptor antagonist, and compositions and methods for use in treatment of Alzheimer's disease (AD), e.g., in a subject who has AD or who is at risk for developing AD.
Resumen de: US2025172555A1
The present invention relates to a lateral flow test device capable of detecting the presence or absence of unfolded p53 in a liquid sample, such as a blood sample. Also provided are methods of using such a device for quantitative or qualitative measurement of U-p53 in a liquid sample. Detection of the presence of this analyte in the sample identifies if the subject has a risk to develop Alzheimer's Disease, and also is useful to confirm a diagnosis of Alzheimer's disease.
Resumen de: US2025172549A1
The present disclosure provides a system comprising a communication interface and computer for assigning a label to the biomolecule fingerprint, wherein the label corresponds to a biological state. The present disclosure also provides a sensor arrays for detecting biomolecules and methods of use. In some embodiments, the sensor arrays are capable of determining a disease state in a subject.
Nº publicación: US2025170124A1 29/05/2025
Solicitante:
THE GENERAL HOSPITAL CORP [US]
The General Hospital Corporation
Resumen de: US2025170124A1
This disclosure provides compounds, pharmaceutical compositions, imaging compositions and methods useful for the diagnosis and/or treatment of neurodegenerative diseases. In particular, this disclosure provides compounds, including radiolabeled compounds, compositions, and methods useful for the diagnosis and/or treatment of neurodegenerative diseases associated with a-synuclein aggregation, such as Parkinson's disease, dementia with Lewy bodies, multiple systems atrophy or prodromal REM sleep behavior disorder.
BOPI
Sede Electrónica
